FDA Warning on Xylazine: Mitigating Human Risk | by: Sumeet Singh, Founder & Chairman | Article Posted: November 6, 2023 | The U.S. Food and Drug Administration (FDA) has issued a warning regarding mitigating risks from human Xylazine exposure. FDA has not...
NABP / Optum Rx VAWD Lawsuit Three generic drug wholesalers, Oak Drugs (“Oak”), Matrix Distributors (“Matrix”), and Primed Pharmaceuticals...
Post VAWD Requirement: Insight and Strategies After an eventful 27 months, OptumRx's VAWD requirement will likely be fully enforced on vendors of...
Optum Rx/VAWD Questions & Answers from July Webinar 1. Are there states other than NY that have legislation that makes it difficult for Optum to...
Pharma Solutions to Advance its VAWD Accreditation Solution Philadelphia, PA – May 25, 2017 – Pharma Solutions LLC, an innovative consulting firm...
NABP Violating DSCSA, Lawsuit Pending Companies are starting to line up for a class action suit against the NABP, potentially reaching over 50...
OptumRX to Offer 3rd Extension to VAWD Requirement Starting March 21 at 11:30 AM, OptumRX began sending the third wave of extension documentation....
